These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 36897609)

  • 1. Biogenic materials for CRISPR delivery and therapeutics.
    Yang K; Qian J; Zhang C; Wang Z; Huang Q; Shi G; Zhang Z; Yang Y; Han X
    Biomater Sci; 2023 May; 11(9):3016-3033. PubMed ID: 36897609
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics.
    Chen F; Alphonse M; Liu Q
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2020 May; 12(3):e1609. PubMed ID: 31797562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Promise and Challenge of In Vivo Delivery for Genome Therapeutics.
    Wilson RC; Gilbert LA
    ACS Chem Biol; 2018 Feb; 13(2):376-382. PubMed ID: 29019396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.
    Givens BE; Naguib YW; Geary SM; Devor EJ; Salem AK
    AAPS J; 2018 Oct; 20(6):108. PubMed ID: 30306365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid-Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Components.
    Kazemian P; Yu SY; Thomson SB; Birkenshaw A; Leavitt BR; Ross CJD
    Mol Pharm; 2022 Jun; 19(6):1669-1686. PubMed ID: 35594500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pre-clinical non-viral vectors exploited for
    Rouatbi N; McGlynn T; Al-Jamal KT
    Biomater Sci; 2022 Jun; 10(13):3410-3432. PubMed ID: 35604372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR/Cas gene editing and delivery systems for cancer therapy.
    Li Y; Zhou S; Wu Q; Gong C
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2024; 16(1):e1938. PubMed ID: 38456346
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in the delivery and applications of nonviral CRISPR/Cas9 gene editing.
    Sinclair F; Begum AA; Dai CC; Toth I; Moyle PM
    Drug Deliv Transl Res; 2023 May; 13(5):1500-1519. PubMed ID: 36988873
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications.
    Liu C; Zhang L; Liu H; Cheng K
    J Control Release; 2017 Nov; 266():17-26. PubMed ID: 28911805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
    Shalaby K; Aouida M; El-Agnaf O
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Delivery of CRISPR/Cas9 for therapeutic genome editing.
    Xu X; Wan T; Xin H; Li D; Pan H; Wu J; Ping Y
    J Gene Med; 2019 Jul; 21(7):e3107. PubMed ID: 31237055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Genome Editing and In Vivo Delivery.
    Ramirez-Phillips AC; Liu D
    AAPS J; 2021 Jun; 23(4):80. PubMed ID: 34080099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-based nanocarrier mediated CRISPR/Cas9 delivery for cancer therapy.
    Aziz A; Rehman U; Sheikh A; Abourehab MAS; Kesharwani P
    J Biomater Sci Polym Ed; 2023 Feb; 34(3):398-418. PubMed ID: 36083788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral and Non-Viral Systems to Deliver Gene Therapeutics to Clinical Targets.
    Taghdiri M; Mussolino C
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000440
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene editing therapeutics based on mRNA delivery.
    Popovitz J; Sharma R; Hoshyar R; Soo Kim B; Murthy N; Lee K
    Adv Drug Deliv Rev; 2023 Sep; 200():115026. PubMed ID: 37516409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CRISPR/Cas System for Genome Editing: Progress and Prospects as a Therapeutic Tool.
    Sahel DK; Mittal A; Chitkara D
    J Pharmacol Exp Ther; 2019 Sep; 370(3):725-735. PubMed ID: 31122933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rational designs of in vivo CRISPR-Cas delivery systems.
    Xu CF; Chen GJ; Luo YL; Zhang Y; Zhao G; Lu ZD; Czarna A; Gu Z; Wang J
    Adv Drug Deliv Rev; 2021 Jan; 168():3-29. PubMed ID: 31759123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 therapeutics: progress and prospects.
    Li T; Yang Y; Qi H; Cui W; Zhang L; Fu X; He X; Liu M; Li PF; Yu T
    Signal Transduct Target Ther; 2023 Jan; 8(1):36. PubMed ID: 36646687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonviral Nanoparticles for CRISPR-Based Genome Editing: Is It Just a Simple Adaption of What Have Been Developed for Nucleic Acid Delivery?
    Qiu M; Glass Z; Xu Q
    Biomacromolecules; 2019 Sep; 20(9):3333-3339. PubMed ID: 31342740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Viral Vectors, Engineered Cells and the CRISPR Revolution.
    DiCarlo JE; Deeconda A; Tsang SH
    Adv Exp Med Biol; 2017; 1016():3-27. PubMed ID: 29130151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.